25 XP   0   0   10

Tanvex BioPharma Inc
Buy, Hold or Sell?

Let's analyse Tanvex together

PenkeI guess you are interested in Tanvex BioPharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Tanvex BioPharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Tanvex BioPharma Inc

I send you an email if I find something interesting about Tanvex BioPharma Inc.

Quick analysis of Tanvex (30 sec.)










What can you expect buying and holding a share of Tanvex? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
NT$6.07
Expected worth in 1 year
NT$1.85
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
NT$-4.22
Return On Investment
-8.9%

For what price can you sell your share?

Current Price per Share
NT$47.20
Expected price per share
NT$33.00 - NT$57.80
How sure are you?
50%

1. Valuation of Tanvex (5 min.)




Live pricePrice per Share (EOD)

NT$47.20

Intrinsic Value Per Share

NT$-148.86 - NT$-176.29

Total Value Per Share

NT$-142.79 - NT$-170.22

2. Growth of Tanvex (5 min.)




Is Tanvex growing?

Current yearPrevious yearGrowGrow %
How rich?$25.2m$60.9m-$22.6m-59.3%

How much money is Tanvex making?

Current yearPrevious yearGrowGrow %
Making money-$16.4m-$12.5m-$3.8m-23.2%
Net Profit Margin-5,144.3%-8,887.0%--

How much money comes from the company's main activities?

3. Financial Health of Tanvex (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#550 / 1010

Most Revenue
#551 / 1010

Most Profit
#650 / 1010

Most Efficient
#909 / 1010

What can you expect buying and holding a share of Tanvex? (5 min.)

Welcome investor! Tanvex's management wants to use your money to grow the business. In return you get a share of Tanvex.

What can you expect buying and holding a share of Tanvex?

First you should know what it really means to hold a share of Tanvex. And how you can make/lose money.

Speculation

The Price per Share of Tanvex is NT$47.20. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Tanvex.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Tanvex, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$6.07. Based on the TTM, the Book Value Change Per Share is NT$-1.05 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.59 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Tanvex.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps-0.12-0.2%-0.12-0.3%-0.05-0.1%-0.07-0.1%-0.07-0.1%
Usd Book Value Change Per Share-0.12-0.3%-0.03-0.1%0.020.0%0.010.0%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.12-0.3%-0.03-0.1%0.020.0%0.010.0%0.010.0%
Usd Price Per Share2.00-2.20-1.59-1.78-1.78-
Price to Earnings Ratio-4.25--4.53--10.47--8.15--8.15-
Price-to-Total Gains Ratio-16.02--13.01--48.20--19.64--19.64-
Price to Book Ratio10.73-8.44-7.86-7.12-7.12-
Price-to-Total Gains Ratio-16.02--13.01--48.20--19.64--19.64-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.44904
Number of shares690
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.01
Usd Total Gains Per Share-0.030.01
Gains per Quarter (690 shares)-22.336.43
Gains per Year (690 shares)-89.3125.72
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-89-9902616
20-179-18805142
30-268-27707768
40-357-366010394
50-447-4550129120
60-536-5440154146
70-625-6330180172
80-715-7220206198
90-804-8110231224
100-893-9000257250

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.020.00.00.0%0.020.00.00.0%
Book Value Change Per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%6.014.00.030.0%6.014.00.030.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.020.00.0%0.00.020.00.0%
Total Gains per Share1.03.00.025.0%3.09.00.025.0%6.014.00.030.0%6.014.00.030.0%6.014.00.030.0%

Fundamentals of Tanvex

About Tanvex BioPharma Inc

Tanvex BioPharma, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and sale of biosimilar products in Taiwan and the United States. The company focuses on delivering biosimilars which target neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis. Its products pipeline includes TX01 and TX-05 which have completed Phase III clinical trials; TX-04 and TX-16 that are in Phase I clinical trial; and TX-52 and other products which are in pre-clinical trial. The company was formerly known as Ruenvex Biotech, Inc. Tanvex BioPharma, Inc. was incorporated in 2013 and is based in George Town, the Cayman Islands.

Fundamental data was last updated by Penke on 2024-04-18 16:58:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Tanvex BioPharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Tanvex earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Tanvex to the Biotechnology industry mean.
  • A Net Profit Margin of -5,700.6% means that NT$-57.01 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tanvex BioPharma Inc:

  • The MRQ is -5,700.6%. The company is making a huge loss. -2
  • The TTM is -5,144.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-5,700.6%TTM-5,144.3%-556.3%
TTM-5,144.3%YOY-8,887.0%+3,742.7%
TTM-5,144.3%5Y-14,315.0%+9,170.6%
5Y-14,315.0%10Y-14,315.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-5,700.6%-200.1%-5,500.5%
TTM-5,144.3%-216.8%-4,927.5%
YOY-8,887.0%-288.3%-8,598.7%
5Y-14,315.0%-449.1%-13,865.9%
10Y-14,315.0%-605.5%-13,709.5%
1.1.2. Return on Assets

Shows how efficient Tanvex is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tanvex to the Biotechnology industry mean.
  • -18.7% Return on Assets means that Tanvex generated NT$-0.19 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tanvex BioPharma Inc:

  • The MRQ is -18.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -16.9%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-18.7%TTM-16.9%-1.9%
TTM-16.9%YOY-10.5%-6.4%
TTM-16.9%5Y-14.3%-2.6%
5Y-14.3%10Y-14.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-18.7%-13.3%-5.4%
TTM-16.9%-12.8%-4.1%
YOY-10.5%-11.7%+1.2%
5Y-14.3%-13.9%-0.4%
10Y-14.3%-15.7%+1.4%
1.1.3. Return on Equity

Shows how efficient Tanvex is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tanvex to the Biotechnology industry mean.
  • -63.1% Return on Equity means Tanvex generated NT$-0.63 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tanvex BioPharma Inc:

  • The MRQ is -63.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -47.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-63.1%TTM-47.3%-15.8%
TTM-47.3%YOY-22.2%-25.1%
TTM-47.3%5Y-26.0%-21.2%
5Y-26.0%10Y-26.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-63.1%-16.9%-46.2%
TTM-47.3%-16.1%-31.2%
YOY-22.2%-15.1%-7.1%
5Y-26.0%-19.3%-6.7%
10Y-26.0%-20.2%-5.8%

1.2. Operating Efficiency of Tanvex BioPharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Tanvex is operating .

  • Measures how much profit Tanvex makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tanvex to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tanvex BioPharma Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-1,230.8%+1,230.8%
TTM-1,230.8%YOY-8,728.3%+7,497.4%
TTM-1,230.8%5Y-13,351.4%+12,120.6%
5Y-13,351.4%10Y-13,351.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--296.2%+296.2%
TTM-1,230.8%-232.5%-998.3%
YOY-8,728.3%-298.2%-8,430.1%
5Y-13,351.4%-492.1%-12,859.3%
10Y-13,351.4%-632.4%-12,719.0%
1.2.2. Operating Ratio

Measures how efficient Tanvex is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 55.77 means that the operating costs are NT$55.77 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Tanvex BioPharma Inc:

  • The MRQ is 55.772. The company is inefficient in keeping operating costs low. -1
  • The TTM is 51.897. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ55.772TTM51.897+3.874
TTM51.897YOY90.731-38.834
TTM51.8975Y142.341-90.444
5Y142.34110Y142.3410.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ55.7723.231+52.541
TTM51.8973.310+48.587
YOY90.7313.890+86.841
5Y142.3415.739+136.602
10Y142.3417.876+134.465

1.3. Liquidity of Tanvex BioPharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Tanvex is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.66 means the company has NT$1.66 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Tanvex BioPharma Inc:

  • The MRQ is 1.661. The company is able to pay all its short-term debts. +1
  • The TTM is 3.026. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ1.661TTM3.026-1.365
TTM3.026YOY6.123-3.096
TTM3.0265Y6.729-3.703
5Y6.72910Y6.7290.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6613.890-2.229
TTM3.0264.173-1.147
YOY6.1235.344+0.779
5Y6.7296.126+0.603
10Y6.7296.448+0.281
1.3.2. Quick Ratio

Measures if Tanvex is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tanvex to the Biotechnology industry mean.
  • A Quick Ratio of 0.03 means the company can pay off NT$0.03 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tanvex BioPharma Inc:

  • The MRQ is 0.026. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.063. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.026TTM0.063-0.037
TTM0.063YOY0.135-0.073
TTM0.0635Y0.857-0.795
5Y0.85710Y0.8570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0263.514-3.488
TTM0.0633.998-3.935
YOY0.1355.380-5.245
5Y0.8576.105-5.248
10Y0.8576.404-5.547

1.4. Solvency of Tanvex BioPharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Tanvex assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tanvex to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.70 means that Tanvex assets are financed with 70.3% credit (debt) and the remaining percentage (100% - 70.3%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tanvex BioPharma Inc:

  • The MRQ is 0.703. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.622. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.703TTM0.622+0.081
TTM0.622YOY0.509+0.113
TTM0.6225Y0.396+0.226
5Y0.39610Y0.3960.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7030.339+0.364
TTM0.6220.336+0.286
YOY0.5090.271+0.238
5Y0.3960.366+0.030
10Y0.3960.389+0.007
1.4.2. Debt to Equity Ratio

Measures if Tanvex is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tanvex to the Biotechnology industry mean.
  • A Debt to Equity ratio of 236.5% means that company has NT$2.37 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tanvex BioPharma Inc:

  • The MRQ is 2.365. The company is just not able to pay all its debts with equity.
  • The TTM is 1.729. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ2.365TTM1.729+0.636
TTM1.729YOY1.066+0.664
TTM1.7295Y0.822+0.908
5Y0.82210Y0.8220.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.3650.388+1.977
TTM1.7290.402+1.327
YOY1.0660.335+0.731
5Y0.8220.426+0.396
10Y0.8220.461+0.361

2. Market Valuation of Tanvex BioPharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Tanvex generates.

  • Above 15 is considered overpriced but always compare Tanvex to the Biotechnology industry mean.
  • A PE ratio of -4.25 means the investor is paying NT$-4.25 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tanvex BioPharma Inc:

  • The EOD is -3.081. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.250. Based on the earnings, the company is expensive. -2
  • The TTM is -4.533. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.081MRQ-4.250+1.169
MRQ-4.250TTM-4.533+0.283
TTM-4.533YOY-10.469+5.936
TTM-4.5335Y-8.154+3.621
5Y-8.15410Y-8.1540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.081-2.264-0.817
MRQ-4.250-2.629-1.621
TTM-4.533-2.680-1.853
YOY-10.469-4.145-6.324
5Y-8.154-6.257-1.897
10Y-8.154-6.254-1.900
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Tanvex BioPharma Inc:

  • The EOD is -3.651. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.036. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.566. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-3.651MRQ-5.036+1.385
MRQ-5.036TTM-6.566+1.530
TTM-6.566YOY-11.347+4.782
TTM-6.5665Y-9.356+2.790
5Y-9.35610Y-9.3560.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-3.651-2.973-0.678
MRQ-5.036-3.333-1.703
TTM-6.566-3.553-3.013
YOY-11.347-5.605-5.742
5Y-9.356-8.376-0.980
10Y-9.356-8.865-0.491
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Tanvex is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 10.73 means the investor is paying NT$10.73 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Tanvex BioPharma Inc:

  • The EOD is 7.776. Based on the equity, the company is overpriced. -1
  • The MRQ is 10.725. Based on the equity, the company is expensive. -2
  • The TTM is 8.442. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD7.776MRQ10.725-2.949
MRQ10.725TTM8.442+2.283
TTM8.442YOY7.864+0.579
TTM8.4425Y7.117+1.325
5Y7.11710Y7.1170.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD7.7761.896+5.880
MRQ10.7252.115+8.610
TTM8.4422.093+6.349
YOY7.8642.884+4.980
5Y7.1173.542+3.575
10Y7.1173.916+3.201
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Tanvex BioPharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---4.064-1.054-74%0.589-790%0.303-1439%0.303-1439%
Book Value Per Share--6.0709.206-34%7.213-16%8.812-31%8.812-31%
Current Ratio--1.6613.026-45%6.123-73%6.729-75%6.729-75%
Debt To Asset Ratio--0.7030.622+13%0.509+38%0.396+77%0.396+77%
Debt To Equity Ratio--2.3651.729+37%1.066+122%0.822+188%0.822+188%
Dividend Per Share----0%-0%-0%-0%
Eps---3.829-3.949+3%-1.708-55%-2.197-43%-2.197-43%
Free Cash Flow Per Share---3.232-2.782-14%-1.391-57%-1.781-45%-1.781-45%
Free Cash Flow To Equity Per Share---3.232-0.679-79%-1.508-53%-0.879-73%-0.879-73%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---176.291--------
Intrinsic Value_10Y_min---148.862--------
Intrinsic Value_1Y_max---8.549--------
Intrinsic Value_1Y_min---8.392--------
Intrinsic Value_3Y_max---32.633--------
Intrinsic Value_3Y_min---31.014--------
Intrinsic Value_5Y_max---65.095--------
Intrinsic Value_5Y_min---59.822--------
Market Cap6385074022.400-38%8806532179.2009679068777.600-9%16362529062.850-46%14707105466.785-40%14707105466.785-40%
Net Profit Margin---57.006-51.443-10%-88.870+56%-143.150+151%-143.150+151%
Operating Margin----12.3080%-87.2830%-133.5140%-133.5140%
Operating Ratio--55.77251.897+7%90.731-39%142.341-61%142.341-61%
Pb Ratio7.776-38%10.7258.442+27%7.864+36%7.117+51%7.117+51%
Pe Ratio-3.081+27%-4.250-4.533+7%-10.469+146%-8.154+92%-8.154+92%
Price Per Share47.200-38%65.10071.550-9%51.825+26%57.822+13%57.822+13%
Price To Free Cash Flow Ratio-3.651+27%-5.036-6.566+30%-11.347+125%-9.356+86%-9.356+86%
Price To Total Gains Ratio-11.614+27%-16.018-13.008-19%-48.198+201%-19.635+23%-19.635+23%
Quick Ratio--0.0260.063-59%0.135-81%0.857-97%0.857-97%
Return On Assets---0.187-0.169-10%-0.105-44%-0.143-24%-0.143-24%
Return On Equity---0.631-0.473-25%-0.222-65%-0.260-59%-0.260-59%
Total Gains Per Share---4.064-1.054-74%0.589-790%0.303-1439%0.303-1439%
Usd Book Value--25208077.00038231815.200-34%60904939.475-59%67647944.270-63%67647944.270-63%
Usd Book Value Change Per Share---0.125-0.032-74%0.018-790%0.009-1439%0.009-1439%
Usd Book Value Per Share--0.1860.283-34%0.221-16%0.271-31%0.271-31%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.118-0.121+3%-0.052-55%-0.067-43%-0.067-43%
Usd Free Cash Flow---13421978.600-11551995.550-14%-10974682.050-18%-12586725.235-6%-12586725.235-6%
Usd Free Cash Flow Per Share---0.099-0.085-14%-0.043-57%-0.055-45%-0.055-45%
Usd Free Cash Flow To Equity Per Share---0.099-0.021-79%-0.046-53%-0.027-73%-0.027-73%
Usd Market Cap196021772.488-38%270360537.901297147411.472-9%502329642.229-46%451508137.830-40%451508137.830-40%
Usd Price Per Share1.449-38%1.9992.197-9%1.591+26%1.775+13%1.775+13%
Usd Profit---15903121.900-16402250.175+3%-12595672.750-21%-14889352.640-6%-14889352.640-6%
Usd Revenue--278970.900471329.425-41%171950.700+62%137414.735+103%137414.735+103%
Usd Total Gains Per Share---0.125-0.032-74%0.018-790%0.009-1439%0.009-1439%
 EOD+3 -5MRQTTM+4 -28YOY+5 -275Y+5 -2710Y+5 -27

3.2. Fundamental Score

Let's check the fundamental score of Tanvex BioPharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-3.081
Price to Book Ratio (EOD)Between0-17.776
Net Profit Margin (MRQ)Greater than0-57.006
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.026
Current Ratio (MRQ)Greater than11.661
Debt to Asset Ratio (MRQ)Less than10.703
Debt to Equity Ratio (MRQ)Less than12.365
Return on Equity (MRQ)Greater than0.15-0.631
Return on Assets (MRQ)Greater than0.05-0.187
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of Tanvex BioPharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.454
Ma 20Greater thanMa 5048.170
Ma 50Greater thanMa 10054.371
Ma 100Greater thanMa 20060.688
OpenGreater thanClose47.300
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets2,763,403
Total Liabilities1,942,293
Total Stockholder Equity821,110
 As reported
Total Liabilities 1,942,293
Total Stockholder Equity+ 821,110
Total Assets = 2,763,403

Assets

Total Assets2,763,403
Total Current Assets604,212
Long-term Assets2,159,191
Total Current Assets
Cash And Cash Equivalents 380,752
Net Receivables 9,396
Inventory 108,285
Total Current Assets  (as reported)604,212
Total Current Assets  (calculated)498,433
+/- 105,779
Long-term Assets
Property Plant Equipment 1,928,141
Long-term Assets Other 17,259
Long-term Assets  (as reported)2,159,191
Long-term Assets  (calculated)1,945,400
+/- 213,791

Liabilities & Shareholders' Equity

Total Current Liabilities363,730
Long-term Liabilities1,578,563
Total Stockholder Equity821,110
Total Current Liabilities
Other Current Liabilities 396
Total Current Liabilities  (as reported)363,730
Total Current Liabilities  (calculated)396
+/- 363,334
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,731,781
Long-term Liabilities  (as reported)1,578,563
Long-term Liabilities  (calculated)1,731,781
+/- 153,218
Total Stockholder Equity
Total Stockholder Equity (as reported)821,110
Total Stockholder Equity (calculated)0
+/- 821,110
Other
Capital Stock1,339,629
Common Stock Shares Outstanding 133,963
Net Invested Capital 821,110
Net Working Capital 240,482
Property Plant and Equipment Gross 1,928,141



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-31
> Total Assets 
4,397,547
3,864,084
3,218,244
3,572,993
2,992,568
2,462,147
1,997,059
4,372,725
3,885,768
3,462,962
5,080,708
4,713,589
4,449,611
4,143,812
3,973,415
3,419,816
2,946,309
3,742,046
3,443,425
2,763,403
2,763,4033,443,4253,742,0462,946,3093,419,8163,973,4154,143,8124,449,6114,713,5895,080,7083,462,9623,885,7684,372,7251,997,0592,462,1472,992,5683,572,9933,218,2443,864,0844,397,547
   > Total Current Assets 
3,288,186
2,799,386
2,196,991
2,604,974
2,063,554
1,579,355
1,032,743
2,263,513
1,802,376
1,444,016
2,707,053
2,401,988
2,105,258
1,563,129
1,488,046
1,043,719
657,751
1,483,327
1,132,696
604,212
604,2121,132,6961,483,327657,7511,043,7191,488,0461,563,1292,105,2582,401,9882,707,0531,444,0161,802,3762,263,5131,032,7431,579,3552,063,5542,604,9742,196,9912,799,3863,288,186
       Cash And Cash Equivalents 
1,139,080
1,261,331
1,036,054
2,427,451
1,852,631
1,410,917
771,772
2,068,608
1,635,067
1,301,921
2,571,110
2,222,977
1,893,283
1,305,150
1,171,076
786,233
426,518
1,219,873
873,784
380,752
380,752873,7841,219,873426,518786,2331,171,0761,305,1501,893,2832,222,9772,571,1101,301,9211,635,0672,068,608771,7721,410,9171,852,6312,427,4511,036,0541,261,3311,139,080
       Short-term Investments 
1,914,560
1,301,580
931,500
0
0
0
55,168
0
15,344
15,021
0
0
0
0
0
0
0
0
0
0
000000000015,02115,344055,168000931,5001,301,5801,914,560
       Net Receivables 
0
0
30,098
1,290
1,507
1,725
1,920
1,909
2,191
975
972
27,835
34,428
29,971
47,381
27,639
27,682
36,931
0
9,396
9,396036,93127,68227,63947,38129,97134,42827,8359729752,1911,9091,9201,7251,5071,29030,09800
       Inventory 
44,550
47,509
62,467
52,203
57,879
51,738
49,748
50,082
52,092
50,933
62,144
90,331
125,966
172,111
198,501
170,841
141,180
141,902
133,110
108,285
108,285133,110141,902141,180170,841198,501172,111125,96690,33162,14450,93352,09250,08249,74851,73857,87952,20362,46747,50944,550
   > Long-term Assets 
1,109,361
1,064,698
1,021,253
968,019
929,014
882,792
964,316
2,109,212
2,083,392
2,018,946
2,373,655
2,311,601
2,344,353
2,580,683
2,485,369
2,376,097
2,288,558
2,258,719
2,310,729
2,159,191
2,159,1912,310,7292,258,7192,288,5582,376,0972,485,3692,580,6832,344,3532,311,6012,373,6552,018,9462,083,3922,109,212964,316882,792929,014968,0191,021,2531,064,6981,109,361
       Property Plant Equipment 
1,061,083
1,017,848
975,665
922,960
879,123
839,454
805,439
1,906,277
1,878,195
1,819,952
2,175,929
2,113,852
2,138,283
2,166,093
2,251,395
2,150,560
2,063,608
2,032,161
2,059,751
1,928,141
1,928,1412,059,7512,032,1612,063,6082,150,5602,251,3952,166,0932,138,2832,113,8522,175,9291,819,9521,878,1951,906,277805,439839,454879,123922,960975,6651,017,8481,061,083
       Other Assets 
29,341
27,585
27,633
29,127
35,142
30,028
145,512
190,978
193,703
187,956
187,225
187,582
194,097
402,589
220,980
213,468
212,832
214,476
0
0
00214,476212,832213,468220,980402,589194,097187,582187,225187,956193,703190,978145,51230,02835,14229,12727,63327,58529,341
> Total Liabilities 
627,808
563,916
547,247
542,122
528,715
605,894
577,006
1,752,010
1,637,287
1,618,582
1,947,532
1,918,794
1,957,610
1,979,620
2,085,591
2,028,336
1,947,563
1,951,455
2,072,528
1,942,293
1,942,2932,072,5281,951,4551,947,5632,028,3362,085,5911,979,6201,957,6101,918,7941,947,5321,618,5821,637,2871,752,010577,006605,894528,715542,122547,247563,916627,808
   > Total Current Liabilities 
282,001
247,439
249,835
270,448
267,940
305,207
308,299
353,099
228,407
290,394
237,070
248,514
239,265
236,168
264,229
303,285
286,508
287,658
378,567
363,730
363,730378,567287,658286,508303,285264,229236,168239,265248,514237,070290,394228,407353,099308,299305,207267,940270,448249,835247,439282,001
       Short Long Term Debt 
0
0
0
0
0
36,512
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000036,51200000
       Other Current Liabilities 
74,487
0
27,477
19,723
17,846
24,766
32,762
21,602
18,356
23,143
24,114
22,282
35,047
33,001
46,990
62,701
24,674
26,136
417
396
39641726,13624,67462,70146,99033,00135,04722,28224,11423,14318,35621,60232,76224,76617,84619,72327,477074,487
   > Long-term Liabilities 
345,807
316,477
297,412
271,674
260,775
300,687
268,707
1,398,911
1,408,880
1,328,188
1,710,462
1,670,280
1,718,345
1,743,452
1,821,362
1,725,051
1,661,055
1,663,797
1,693,961
1,578,563
1,578,5631,693,9611,663,7971,661,0551,725,0511,821,3621,743,4521,718,3451,670,2801,710,4621,328,1881,408,8801,398,911268,707300,687260,775271,674297,412316,477345,807
       Capital Lease Obligations Min Short Term Debt
420,294
388,664
371,595
342,740
326,983
301,059
278,570
1,429,112
1,425,602
1,400,460
1,787,190
1,759,026
1,801,051
1,834,777
1,927,838
1,839,236
1,794,037
1,814,336
1,849,655
1,731,781
1,731,7811,849,6551,814,3361,794,0371,839,2361,927,8381,834,7771,801,0511,759,0261,787,1901,400,4601,425,6021,429,112278,570301,059326,983342,740371,595388,664420,294
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
12,679
11,067
8,259
10,469
0
0
0
0
000010,4698,25911,06712,679000000000000
> Total Stockholder Equity
3,769,739
3,300,168
2,670,997
3,030,871
2,463,853
1,856,253
1,420,053
2,620,715
2,248,481
1,844,380
3,133,176
2,794,795
2,492,001
2,164,192
1,887,824
1,391,480
998,746
1,790,591
1,370,897
821,110
821,1101,370,8971,790,591998,7461,391,4801,887,8242,164,1922,492,0012,794,7953,133,1761,844,3802,248,4812,620,7151,420,0531,856,2532,463,8533,030,8712,670,9973,300,1683,769,739
   Common Stock
2,439,141
2,439,741
2,440,521
2,642,041
2,642,101
2,643,151
2,645,379
3,116,067
3,118,277
3,120,047
3,524,247
3,524,547
3,525,007
3,525,116
3,526,091
3,526,606
1,176,654
1,336,654
0
0
001,336,6541,176,6543,526,6063,526,0913,525,1163,525,0073,524,5473,524,2473,120,0473,118,2773,116,0672,645,3792,643,1512,642,1012,642,0412,440,5212,439,7412,439,141
   Retained Earnings Total Equity00000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000
   Capital Surplus 00000000000000000000
   Treasury Stock00000000000000000000
   Other Stockholders Equity 00-209,562-235,649-227,089-185,294-287,804-368,550-390,122-384,597-380,319-337,086-364,038-332,597-309,582-262,194-279,382-198,901-205,948-220,014



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue61,411
Cost of Revenue-1,710
Gross Profit59,70159,701
 
Operating Income (+$)
Gross Profit59,701
Operating Expense-2,162,161
Operating Income-2,100,750-2,102,460
 
Operating Expense (+$)
Research Development1,706,743
Selling General Administrative453,708
Selling And Marketing Expenses0
Operating Expense2,162,1612,160,451
 
Net Interest Income (+$)
Interest Income29,040
Interest Expense-57,384
Other Finance Cost-0
Net Interest Income-28,344
 
Pretax Income (+$)
Operating Income-2,100,750
Net Interest Income-28,344
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-2,136,673-2,100,750
EBIT - interestExpense = -57,384
-2,137,101
-2,079,717
Interest Expense57,384
Earnings Before Interest and Taxes (EBIT)0-2,079,289
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-2,136,673
Tax Provision-428
Net Income From Continuing Ops-2,137,101-2,137,101
Net Income-2,137,101
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net028,344
 

Technical Analysis of Tanvex
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Tanvex. The general trend of Tanvex is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Tanvex's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Tanvex BioPharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 48.05 < 51.20 < 57.80.

The bearish price targets are: 35.40 > 34.65 > 33.00.

Tweet this
Tanvex BioPharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Tanvex BioPharma Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Tanvex BioPharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Tanvex BioPharma Inc. The current macd is -1.96792714.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Tanvex price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Tanvex. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Tanvex price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Tanvex BioPharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartTanvex BioPharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Tanvex BioPharma Inc. The current adx is 45.58.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -3/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Tanvex shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bearish trend. The ADX is declining, the bearish trend is weakening. Could be a potential reversal to the upside. -2
Tanvex BioPharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Tanvex BioPharma Inc. The current sar is 48.85.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Tanvex BioPharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Tanvex BioPharma Inc. The current rsi is 39.45. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Tanvex BioPharma Inc Daily Relative Strength Index (RSI) ChartTanvex BioPharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Tanvex BioPharma Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 2/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Tanvex price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Tanvex BioPharma Inc Daily Stochastic Oscillator ChartTanvex BioPharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Tanvex BioPharma Inc. The current cci is -57.85863406.

Tanvex BioPharma Inc Daily Commodity Channel Index (CCI) ChartTanvex BioPharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Tanvex BioPharma Inc. The current cmo is -12.88211818.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Tanvex BioPharma Inc Daily Chande Momentum Oscillator (CMO) ChartTanvex BioPharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Tanvex BioPharma Inc. The current willr is -52.23880597.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Tanvex is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Tanvex BioPharma Inc Daily Williams %R ChartTanvex BioPharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Tanvex BioPharma Inc.

Tanvex BioPharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Tanvex BioPharma Inc. The current atr is 1.57142652.

Tanvex BioPharma Inc Daily Average True Range (ATR) ChartTanvex BioPharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Tanvex BioPharma Inc. The current obv is -2,758,728.

Tanvex BioPharma Inc Daily On-Balance Volume (OBV) ChartTanvex BioPharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Tanvex BioPharma Inc. The current mfi is 50.80.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Tanvex BioPharma Inc Daily Money Flow Index (MFI) ChartTanvex BioPharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Tanvex BioPharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-06STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-12MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-02MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-04STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-17CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-10STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-23RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).

6.3. Candlestick Patterns

Tanvex BioPharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Tanvex BioPharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.454
Ma 20Greater thanMa 5048.170
Ma 50Greater thanMa 10054.371
Ma 100Greater thanMa 20060.688
OpenGreater thanClose47.300
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Tanvex with someone you think should read this too:
  • Are you bullish or bearish on Tanvex? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Tanvex? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Tanvex BioPharma Inc

I send you an email if I find something interesting about Tanvex BioPharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Tanvex BioPharma Inc.

Receive notifications about Tanvex BioPharma Inc in your mailbox!